ReviewCurrent atherosclerosis reports2026
GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purpose of reviewLipoprotein(a) [Lp(a)], a predominantly genetically determined biomarker that remains relatively stable throughout life, is a well-established and independent risk factor for cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated broad cardiometabolic benefits, yet their potential influence on Lp(a) remains unclear. This review synthesizes the most recent evidence at the intersection of GLP-1RAs, Lp(a), and cardiovascular disease, with particular emphasis on underlying mechanistic pathways and their potential implications for cardiovascular risk stratification and clinical outcomes. RECENT
findingsBeyond glycemic control, the multisystem effects of GLP-1RAs suggest a plausible influence on Lp(a) metabolism through multiple mechanistic pathways, including modulation of hepatic and intestinal lipoprotein synthesis and secretion, anti-inflammatory and endothelial-protective actions, attenuation of adipokine signaling, and broader metabolic outcomes. Preclinical and early clinical studies suggest modest but significant reductions in Lp(a) with GLP-1RA therapy, and ongoing large-scale studies aim to clarify the magnitude and clinical relevance of this effect. GLP-1RAs may offer a novel approach to addressing residual cardiovascular risk in patients with elevated Lp(a), although their direct effects on Lp(a) remain uncertain and warrant further investigation. Emerging evidence suggests a promising link between GLP-1RA therapy and Lp(a)-related pathways.
Indexed as
Identifiers
42878985What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.